BR9705117A - Lipídeos catiônicos para terapia de gene - Google Patents

Lipídeos catiônicos para terapia de gene

Info

Publication number
BR9705117A
BR9705117A BR9705117A BR9705117A BR9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A BR 9705117 A BR9705117 A BR 9705117A
Authority
BR
Brazil
Prior art keywords
gene therapy
cationic lipids
lipids
cationic
therapy
Prior art date
Application number
BR9705117A
Other languages
English (en)
Inventor
John Otto Link
John Joseph Nestor Jr
Gary Allen Peltz
Paula Nanette Belloni
Donald Roy Hirschfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9705117A publication Critical patent/BR9705117A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24Y being a hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
BR9705117A 1996-10-22 1997-10-22 Lipídeos catiônicos para terapia de gene BR9705117A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2958196P 1996-10-22 1996-10-22

Publications (1)

Publication Number Publication Date
BR9705117A true BR9705117A (pt) 1998-09-15

Family

ID=21849783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9705117A BR9705117A (pt) 1996-10-22 1997-10-22 Lipídeos catiônicos para terapia de gene

Country Status (7)

Country Link
US (1) US6034137A (pt)
EP (1) EP0846680A1 (pt)
JP (1) JPH10152461A (pt)
CN (1) CN1068585C (pt)
AR (1) AR010013A1 (pt)
BR (1) BR9705117A (pt)
CA (1) CA2217550A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
WO2000027795A1 (en) 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
FR2788275B1 (fr) * 1999-01-11 2002-06-14 Lipha ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
WO2003106701A1 (es) * 2002-06-01 2003-12-24 Consejo Superior De Investigaciones Científicas Detección y análisis no invasivo de microorganismos en productos lácteos en envases laminados de papel o cartón utilizando ondas elásticas por acoplamiento en seco.
GB0315783D0 (en) * 2003-07-04 2003-08-13 Norferm Da Use
JP5166022B2 (ja) 2004-05-05 2013-03-21 サイレンス・セラピューティクス・アーゲー 脂質、脂質複合体、およびその使用
EP1793865A4 (en) * 2004-08-05 2009-05-13 Baylor Res Inst GENETIC OR DRUG DELIVERY SYSTEM
BRPI0519468A2 (pt) 2004-12-27 2009-01-27 Silence Therapeutics Ag complexos de lipÍdeos revestido e seu uso
DE602005024794D1 (de) 2005-07-22 2010-12-30 Novagali Pharma Sa Verfahren zur Herstellung von gesättigten und ungesättigten primären Fett-Aminen
WO2008009477A2 (en) 2006-07-21 2008-01-24 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
CA2664632A1 (en) * 2006-09-27 2008-04-03 Paolo Botti Means and methods of enhancing delivery to biological systems
WO2009138806A1 (en) * 2008-05-13 2009-11-19 Dendrigen S.A. Novel liposome cocktail formulations containing doxorubicin and the potent multidrug resistance inhibitor amiodarone
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
JP5889783B2 (ja) * 2009-05-05 2016-03-22 テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation 免疫細胞へオリゴヌクレオチドを送達する方法
BR212012000255U2 (pt) * 2009-07-09 2015-11-03 Marina Biotech Inc lipossomas anfotéricos compreendendo imino lípidos.
EP2567951B1 (en) * 2010-04-28 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
EP2640700B1 (en) 2010-11-15 2018-10-31 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
JP6182457B2 (ja) * 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
EP2792368A4 (en) * 2011-12-12 2015-09-30 Kyowa Hakko Kirin Co Ltd LIPID NANOPARTICLES WITH COMBINATIONS OF CATIONIC LIPIDES
EP2934563B1 (en) * 2012-12-18 2020-07-08 Jawaharlal Nehru Centre for Advanced Scientific Research Antimicrobial compounds, their synthesis and applications thereof
PL3766916T3 (pl) 2014-06-25 2023-02-27 Acuitas Therapeutics Inc. Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016108634A2 (ko) 2014-12-30 2016-07-07 (주)셀트리온 표피성장인자와 리포좀의 하이브리드형 다중층 나노구조체 및 그 제조방법
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CA3061612A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036000A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
JP7543259B2 (ja) * 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
KR20210138569A (ko) 2019-01-11 2021-11-19 아퀴타스 테라퓨틱스 인크. 활성제의 지질 나노입자 전달을 위한 지질
CN111087332B (zh) * 2019-12-11 2021-07-06 东南大学 一种阳离子氨基脂质及其合成方法与应用
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CA3143650A1 (en) * 2021-12-22 2023-06-22 Providence Therapeutics Holdings Inc. Lipids and compositions thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4926046B1 (pt) * 1969-12-30 1974-07-05
DE2808943A1 (de) * 1978-03-02 1979-09-06 Goldschmidt Ag Th Neue guanidiniumsalze, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende mikrobicide zubereitungen
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
US4477428A (en) * 1982-08-26 1984-10-16 Johnson & Johnson Products, Inc. Oral compositions comprising N.sup.α,NG -diacyl derivatives of arginine
GB8312663D0 (en) * 1983-05-09 1983-06-15 Ici Plc Bisbiguanide compounds
GB8312662D0 (en) * 1983-05-09 1983-06-15 Ici Plc Polyether bisbiguanide
JPS60214768A (ja) * 1984-04-07 1985-10-28 Fujisawa Pharmaceut Co Ltd オリゴペプチド化合物
US5141751A (en) * 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5478946A (en) * 1989-06-21 1995-12-26 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
EP0679153A4 (en) * 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
JPH07136604A (ja) * 1993-11-24 1995-05-30 Ebara Corp 洗浄方法及び装置
NZ276975A (en) * 1993-11-24 1998-04-27 Megabios Corp Guanidine based amphiphiles and their use in liposomes for delivering genetic material intracellularly
WO1995028377A1 (en) * 1994-04-18 1995-10-26 Abbott Laboratories Guanidine compounds as regulators of nitric oxide synthase
US5777153A (en) * 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
JP3163230B2 (ja) * 1995-03-13 2001-05-08 科学技術振興事業団 二次元分子パターンの作成方法

Also Published As

Publication number Publication date
MX9708111A (es) 1998-08-30
CA2217550A1 (en) 1998-04-22
JPH10152461A (ja) 1998-06-09
CN1068585C (zh) 2001-07-18
CN1180697A (zh) 1998-05-06
AR010013A1 (es) 2000-05-17
US6034137A (en) 2000-03-07
EP0846680A1 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
BR9705117A (pt) Lipídeos catiônicos para terapia de gene
DE69815075D1 (de) Dimere kationische lipide auf dicystinbasis
BR9612533A (pt) Terapia de combinação para osteoporose
DE69735382D1 (de) Kationische reagenzien zür transfektion
PT849853E (pt) Consola para calhas de suporte
EP1015578A4 (en) THERAPEUTIC MOLECULES
ID24118A (id) Terapi gabungan
NO20004688D0 (no) Terapi ved østrogenassosierte lidelser
BR9605819A (pt) Apoio para cabeça
ID24275A (id) Terapi kombinasi
NO970172D0 (no) Kationiske amfifiler
PT907358E (pt) Terapia de distribuicao uniforme de droga
EP1007028A4 (en) TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
PT9493U (pt) Cabeca para esfregona
NO20006047D0 (no) Fremgangsmåte for genterapi
EP1037631A4 (en) HETEROCYCLIC CATIONIC FATS
BR9508281A (pt) Técnica para autenticação
BR9500251A (pt) Multi-contador para rodas
BR9700690A (pt) Banco para terapia neurológica
ES1031699Y (es) Envase para golosinas
BR9704122A (pt) Estimulador eletro-eletrônico para seios
BR9705606A (pt) Luminária para cromoterapia
BR9505158A (pt) Complexo inorgânico para tratamento de tumores
BR7701696U (pt) Disposição em suporte para fixação de rodízio
ES1029754Y (es) Base para enchufe electrico de seguridad.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.